RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer

Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study ID
NCT05785325
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • RC48-ADC plus Bevacizumab — DRUG
    Administer RC48-ADC intravenously in combination with bevacizumab 5mg/kg once every two weeks.

Study Details

A phase II clinical study of RC48-ADC combined with Bevacizumab as late-line treatment in patients with HER2-expressed metastatic colorectal cancer. A total of 30 patients are planned to be enrolled.

Key Dates

First listed
Mar 27, 2023
Start date
Aug 20, 2023
Status verified
Dec 2022
Primary completion
Dec 1, 2023
Completion
Dec 1, 2024

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: RC48-ADC plus Bevacizumab
    Administer RC48-ADC intravenously in combination with bevacizumab 5mg/kg once every two weeks. Medication must be discontinued until disease progression, intolerable toxicity, informed consent is withdrawn, or investigator judgment is made.

Primary Outcome Measure

Objective Response Rate [ Time Frame: From Baseline to disease progress, up to 18 months ]

Central Contacts

Related Studies